Carregant...
Alternative treatments for melanoma: targeting BCL-2 family members to de-bulk and kill cancer stem cells
For the first time new treatments in melanoma have produced significant responses in advanced diseases, but 30–90% of melanoma patients do not respond or eventually relapse after the initial response to the current treatments. The resistance of these melanomas is likely due to tumor heterogeneity, w...
Guardat en:
| Publicat a: | J Invest Dermatol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4537369/ https://ncbi.nlm.nih.gov/pubmed/25947358 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/jid.2015.145 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|